Ukraine has overpaid some UAH 62 million during state procurement for drugs to treat adults and children with cancer in 2014.

According to an annual analytical report of the Anticorruption Action Center on corruption in the drugs state procurement sector, experts came to the conclusion after comparing the purchase prices of these drugs in neighbor countries. The purchase price of Mycamine 100 milligram (Astellas Pharma Europe) in Ukraine was UAH 11,755, while the price in Russia was UAH 7,309 (in equivalent), UAH 7,661 in Moldova, UAH 5,372 in the Czech Republic; the price of Octagam 10% (Octapharma) in Ukraine is UAH 5,360, in Bulgaria – UAH 3,598 and Slovakia – UAH 3,492; Tasigna 200 milligram (Novartis Pharma) in Ukraine is UAH 738.30, in Russia – UAH 448.76, in Moldova – UAH 513.69; Glivec (Novartis Pharma) in Ukraine – UAH 1,337, in Russia – UAH 1,092, Moldova – UAH 1,097 and in the Czech Republic – UAH 1,151.

According to the center, the state spent UAH 232.473 million for five out of 66 drugs to treat children with cancer, or 63% of expenses (UAH 367.618 million).

The state spent UAH 69.032 million to buy five out of 30 drugs to treat adults with cancer last year, or 40% of total purchases (UAH 173.756 million).

Only two drugs to treat chronic myeloid leukemia were bought for UAH 59.862 million: Tasigna and Glivec.

The experts said in the report that the use of a large part of funds to buy the most "exclusive" drugs is suspicious, taking into account the large overpayment compared to the prices of these drugs in neighbor countries.